Confronto

Histrelin vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

220810-26-4

396091-73-9

Peso molecolare

1323.52 g/mol

1047.21 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Histrelin

Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Histrelin	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Histrelin and Pasireotid?: Histrelin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Histrelin or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Histrelin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Histrelin and Pasireotid in Germany and the United States?: Germania: Histrelin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Histrelin — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Histrelin

Pasireotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Histrelin and Pasireotid?

Histrelin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Histrelin or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Histrelin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Histrelin and Pasireotid in Germany and the United States?

Germania: Histrelin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Histrelin — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.